BDX · Q1 2026 Earnings

Narrative arc: Q3 "executing through headwinds" → Q4 "clear-the-table FY26 reset" → Q1 "pure-play med tech reinvention with Waters cash deployment imminent"

The portfolio framing shifted decisively from "life sciences as integrated business with some weakness" three quarters ago to "pure-play med tech company" this quarter. Last quarter management talked about New BD's algorithm as a forward construct contingent on Waters closing; this quarter it is the operating posture, with the segment reorganization already executed. "BD enters this next chapter as a far more focused pure play med tech company." The signal is that the Waters close is being treated as imminent — management quantified the $2.40/share net impact and laid out the $4B cash distribution ($2B ASR plus $2B debt paydown) as a near-term execution item, not a future scenario.

Operational excellence migrated from a margin-and-cost narrative to a commercial-and-innovation narrative across multiple quarters. Q3 framed BD Excellence as funding reinvestment; Q4 added the $200M two-year cost-out program; this quarter management extended BD Excellence into the commercial organization with a new CRO role ("never existed in the history of BD"), 15% sales force expansion in PI and APM, new compensation plans, and R&D Kaizen events that accelerated launches by 6–12 months. The anchor: "There's another level of performance that we can reach... just like we've always been good operationally. But we're reaching and we're executing at levels that we've never executed at before operationally. We view that same opportunity exists commercially." The shift signals management believes commercial execution — not just operational efficiency — is the next margin lever, which is a more ambitious claim than the cost-out story of prior quarters.

The growth cadence framing reversed from Q4. Last quarter management explicitly told investors Q2 and Q3 would be "the strongest quarters as comps ease" and described a back-half reacceleration. This quarter the language is "no ramp first half to second half in fiscal 2026, with Q2 revenue growth of approximately 2% consistent with full year guidance." That is a meaningful walkback of the Q4 sequencing story and removes the comp-driven acceleration that the FY26 build was supposed to deliver.

Tariff disclosure moved from a directional headwind to a quantified earnings-quality issue. Q3 disclosed FY26 tariffs at ~$275M; Q4 framed them as $185M / ~80bps; this quarter the EPS impact is explicitly quantified at 370bps of the FY26 guide, embedded in the reaffirmed ~25% operating margin. The increased granularity is helpful for modeling but reveals that tariff drag is materially larger as an EPS hit than the operating-margin framing suggested.

Capital allocation pivoted from balanced toward aggressive return. Across three quarters: Q3 was framed as buyback-and-tuck-in M&A; Q4 added an incremental $250M Q1 buyback; this quarter management committed to the $2B ASR plus $2B debt paydown in the near term, on top of the $250M Q1 repurchase already executed. The combined $4B+ deployment over a short window is the most aggressive capital return posture BD has signaled in this coverage window.